Search results for Innovent Biologics

China's Innovent Biologics signs drug deal with Pfizer worth up to $10.5bn

China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials

China’s Innovent Biologics has signed a global collaboration with pharmaceutical giant Pfizer worth up to US$10.5 billion to jointly develop 12 cancer treatment programmes. The Hon...

Pfizer, Innovent strike $10B cancer drug deal

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody

CHENGDU, China, May 12, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical...

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by striking a broad pact that positions it to leverage China’s...

Beigene

Beigene Anonymous (not verified) Mon, 05/25/2026 - 11:38 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

Beigene

Beigene Anonymous (not verified) Thu, 04/30/2026 - 14:18 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

Biogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibody

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building on an existing partnership with local drugmaker TJ Biop...

Pfizer’s $10.5B Deal With One of China’s Top Cancer Biotechs Is Another Sign the Game is Changing

Pfizer unveiled a multi-drug R&D collaboration with Innovent Biologics, making it the latest big pharma company to reach a deal that taps into Chinese labs to source biotech in...

World's First | Mabwell's 9MW5211 Receives FDA Clearance for Clinical Trial Application

SHANGHAI, May 8, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Inves...

<![CDATA[GSK Enters Exclusive Collaboration with SBP Group to Accelerate Bepirovirsen at Launch in Mainland China ]]&...

Struggling Liminatus pays $320M in stock for CAR-T biotech InnocsAI

Cancer immunotherapy company Liminatus Pharma has agreed to pay out shares worth $320 million to buy CAR-T biotech InnocsAI.

<![CDATA[Boehringer Ingelheim Expands Immunology Pipeline With Preclinical Antibody Licensing Deal]]>

BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types

The fight for two tumor types is poised to intensify, with BioNTech lining up a challenge to AstraZeneca and SynOx Therapeutics planning to enter a market served by companies inclu...

Avalyn, in pursuit of better lung drugs, banks $300M in an IPO

The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.

BeOne signs $2B deal for option on preclinical trispecific antibody from China’s Huahui

BeOne Medicines is paying $20 million upfront to reserve the right to buy a preclinical PD-1xCTLA-4xVEGF trispecific antibody from China’s Huahui Health.

<![CDATA[Amgen’s Tarlatamab Approved in China ]]>

Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial

Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boos...

Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors

The Shanghai-based biotech has a cell therapy that, if successful in testing, could become the first treatment of its kind for liver cancer. 

LOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma

SEOUL, South Korea, May 17, 2026 /PRNewswire/ -- LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative...

Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform

Nine years after wowing the audience at the American Society of Clinical Oncology annual meeting with a CAR-T candidate that would become Carvykti—now the world’s most successful c...

AACR: Former Genentech leader engineers startup with vision for ‘smart’ cancer drugs

Just a few years ago, Daniel Chen, M.D., Ph.D., was spending his days in his backyard, sketching out designs for new antibody-drug conjugates with a friend. Now, he’s sharing with...

May 12 2026 - BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal

May 12 2026 - BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal admin Tue, 05/12/2026 - 12:10 Big deals lead the way today, with a massive BMS partners...

Merck ADC, licensed from China, hits mark in first big global trial

The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next deca...